Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP581593.RAjujGq0OReR133UUH6vMEIoMr8zb9X9x6uHIW82zJxZQ130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP581593.RAjujGq0OReR133UUH6vMEIoMr8zb9X9x6uHIW82zJxZQ130_provenance.
• NP312238.RAdJS4unDyNaSc_n7ddNn4M8MiR9D_kYN8dq4bpxfZneA130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP312238.RAdJS4unDyNaSc_n7ddNn4M8MiR9D_kYN8dq4bpxfZneA130_provenance.
• NP436109.RAR10A-QSUwPpCBeeH5S8_YwJ72kTCgRDZBYxNQWJZVMg130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP436109.RAR10A-QSUwPpCBeeH5S8_YwJ72kTCgRDZBYxNQWJZVMg130_provenance.
• NP396021.RALw7aFf2jjYJxTkVZNJ-Szdm1TsCXiltz-R2c4OUBIO4130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP396021.RALw7aFf2jjYJxTkVZNJ-Szdm1TsCXiltz-R2c4OUBIO4130_provenance.
• assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP582695.RA-kJiNi0C7FRxCNn22JHsV29Ii9HFvprw3lBUUZAxZVs130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP582695.RA-kJiNi0C7FRxCNn22JHsV29Ii9HFvprw3lBUUZAxZVs130_provenance.
• assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP389608.RAIyjKgQE5SAPj-ODGMnjnXYsjZ_VGhIJgSFYrSYKiNxI130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP389608.RAIyjKgQE5SAPj-ODGMnjnXYsjZ_VGhIJgSFYrSYKiNxI130_provenance.
• NP898395.RA8FxQ9C96cLALcASSxrIUo8CDMD4S2x83PZBP6XkJqaA130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP898395.RA8FxQ9C96cLALcASSxrIUo8CDMD4S2x83PZBP6XkJqaA130_provenance.
• NP802542.RAxBz3YXuqPGaxAc_us62ohncFfVRaMyZyCDhrs6sJ4UI130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802542.RAxBz3YXuqPGaxAc_us62ohncFfVRaMyZyCDhrs6sJ4UI130_provenance.
• NP680855.RAcN7viPfo4tNtLH-wVGqag8OG_y3AmsDOpZ5tgLvjKUI130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680855.RAcN7viPfo4tNtLH-wVGqag8OG_y3AmsDOpZ5tgLvjKUI130_provenance.
• NP628195.RAEIduGk8gmaDBY0L5kUYyy_f5GSFWYDKzQi08vr29Y3Q130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP628195.RAEIduGk8gmaDBY0L5kUYyy_f5GSFWYDKzQi08vr29Y3Q130_provenance.
• assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1312066.RAY8cWc0E0L525kFa3Ovzd-MwHmSgI4f3eRuY4tWZnotU130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312066.RAY8cWc0E0L525kFa3Ovzd-MwHmSgI4f3eRuY4tWZnotU130_provenance.
• NP1312071.RAcXU6BtKfunEICW54K2x9ka2ejJMY4yd3if64PP8Gdto130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312071.RAcXU6BtKfunEICW54K2x9ka2ejJMY4yd3if64PP8Gdto130_provenance.
• NP1312068.RAu1hemg0uRUb4JleuemNDAoXZShW47pYPrOZP4ZL89RM130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312068.RAu1hemg0uRUb4JleuemNDAoXZShW47pYPrOZP4ZL89RM130_provenance.
• NP1312073.RAkkSijww4cvqQu6ow0cASQrKZUrWKce2Nl7IZIoy0ah0130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312073.RAkkSijww4cvqQu6ow0cASQrKZUrWKce2Nl7IZIoy0ah0130_provenance.
• NP306673.RA1sDhUfkXYNjo4MJ17c8vX4EnrwbMJINKP23FyZBVotk130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP306673.RA1sDhUfkXYNjo4MJ17c8vX4EnrwbMJINKP23FyZBVotk130_provenance.
• NP301070.RAEY8NkpAsbpmlsaExKgWieaBNhspQF58mbALj5XCiMqM130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP301070.RAEY8NkpAsbpmlsaExKgWieaBNhspQF58mbALj5XCiMqM130_provenance.
• NP678173.RAK75KSv_VjEf94gDadS5_pDl4SM0yU9DrpdI9g_yL32c130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP678173.RAK75KSv_VjEf94gDadS5_pDl4SM0yU9DrpdI9g_yL32c130_provenance.
• NP680890.RALDgKpCw70HxmrrmNXIW2mYKZtu09y7fNmP0dfUmwhrI130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680890.RALDgKpCw70HxmrrmNXIW2mYKZtu09y7fNmP0dfUmwhrI130_provenance.
• NP1312069.RAN7gTyaJZVA7s63XUNstuwbWmTK35YpkcoHwD-p4Vm94130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312069.RAN7gTyaJZVA7s63XUNstuwbWmTK35YpkcoHwD-p4Vm94130_provenance.
• NP1312072.RA2JDnaVCkNCICXVDEkaMcu4KrkKIIhot8bdDrYVowDy4130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312072.RA2JDnaVCkNCICXVDEkaMcu4KrkKIIhot8bdDrYVowDy4130_provenance.
• NP1312074.RAygnnkQ7CxWjlU1bQ80XJ4jTeQ-iYrJerlXzM0zkMe3Q130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312074.RAygnnkQ7CxWjlU1bQ80XJ4jTeQ-iYrJerlXzM0zkMe3Q130_provenance.
• NP1312077.RA0j01tBUVQIUOVLUG9sEYXdN0Go0enX1FuVpuj9qgyJI130_assertion description "[From these data we conclude that the occurrence of CDKN2 (p16/MTS1) mutation in primary breast cancer is a rare event and is not likely to be involved in human breast tumour carcinogenesis and progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312077.RA0j01tBUVQIUOVLUG9sEYXdN0Go0enX1FuVpuj9qgyJI130_provenance.